Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

BMRN holding history

Biomarin Pharmaceutical Inc in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

BMRN overviewAll 13F holders of BMRNFull Q2 2026 holdings

Shares (Q2 2026)
1,286,505
Value
$73.6M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of BMRN by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,286,505$73.6M<0.1%−210,347−14.1%ReducedHolders
Q1 20261,496,852$84.6M<0.1%−714,869−32.3%ReducedHolders
Q4 20252,211,721$131.4M<0.1%+671,551+43.6%AddedHolders
Q3 20251,540,170$83.4M<0.1%−155,423−9.2%ReducedHolders
Q2 20251,695,593$93.2M<0.1%+1,579+0.1%AddedHolders
Q1 20251,694,014$119.7M<0.1%+185,381+12.3%AddedHolders
Q4 20241,508,633$99.2M<0.1%+646,662+75.0%AddedHolders
Q3 2024861,971$60.6M<0.1%+476,429+123.6%AddedHolders
Q2 2024385,542$31.7M<0.1%−4,670,897−92.4%ReducedHolders
Q1 20245,056,439$441.6M0.1%+4,963,987+5,369.3%AddedHolders
Q4 202392,452$8.91M<0.1%−152,805−62.3%ReducedHolders
Q3 2023245,257$21.7M<0.1%−24,719−9.2%ReducedHolders
Q2 2023269,976$23.4M<0.1%+74,431+38.1%AddedHolders
Q1 2023195,545$19.0M<0.1%−471,739−70.7%ReducedHolders
Q4 2022667,284$69.1M<0.1%−437,947−39.6%ReducedHolders
Q3 20221,105,231$93.7M0.1%−1,588,293−59.0%ReducedHolders
Q2 20222,693,524$223.2M0.1%−167,979−5.9%ReducedHolders
Q1 20222,861,503$220.6M0.1%+2,697,524+1,645.0%AddedHolders
Q4 2021163,979$14.5M<0.1%−133,514−44.9%ReducedHolders
Q3 2021297,493$23.0M<0.1%+153,667+106.8%AddedHolders
Q2 2021143,826$12.0M<0.1%−51,512−26.4%ReducedHolders
Q1 2021195,338$14.8M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.